Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mondaycom Ltd (MNDY) vs Moderna, Inc. (MRNA) Price & Performance

Mondaycom LtdTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Mondaycom Ltd vs Moderna, Inc. — how do they compare? Mondaycom Ltd trades at $85.96 (market cap $3.70B), while Moderna, Inc. trades at $60.51 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 6.5× Mondaycom Ltd's market cap, and Moderna, Inc. is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals.

MNDYMRNA
Market Cap
$3.70B$24.18B
Sector
TechnologyHealth
52-Week High
$219.15$81.80
52-Week Low
$58.81$22.36
Enterprise Value
$2.86B$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mondaycom Ltd

MNDY trades at $84.52, down 4.63% amid mixed signals. The stock shows strong fundamentals with Q2 2026 EPS of $1.48 beating estimates by 33%, revenue growth of 22% year-over-year, and robust gross margins of 88.74%. However, technical indicators are neutral with support at $83 and resistance at $89. Recent news highlights AI product growth but weaker Q3 revenue guidance caused a sell-off.

Outlook remains cautiously optimistic with a $113.38 consensus price target implying 34% upside. Key risks include slowing revenue growth guidance and competitive pressures. The 76% buy rating from analysts supports long-term potential, but near-term volatility may persist due to execution concerns and market sentiment shifts.

Moderna, Inc.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Mondaycom Ltd

Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.

Read more on MNDY

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA